Publicaciones en las que colabora con Ramón García Sanz (42)

2023

  1. Expert consensus on the integrated diagnosis of idiopathic multicentric Castleman disease

    Revista Espanola de Patologia, Vol. 56, Núm. 3, pp. 158-167

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival

    British Journal of Haematology, Vol. 198, Núm. 2, pp. 278-287

2021

  1. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

    British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852

  2. Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group

    British Journal of Haematology, Vol. 192, Núm. 3, pp. 522-530

  3. Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma

    Cells, Vol. 10, Núm. 3

2020

  1. Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-pembresid clinical trial

    Cancers, Vol. 12, Núm. 12, pp. 1-13

2019

  1. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312

2018

  1. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing

    Haematologica

2017

  1. Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma

    Bone Marrow Transplantation, Vol. 52, Núm. 4, pp. 567-569

  2. Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma

    Clinical Cancer Research, Vol. 23, Núm. 21, pp. 6602-6615

  3. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma

    Haematologica, Vol. 102, Núm. 5, pp. 922-931

2016

  1. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma

    Leukemia, Vol. 30, Núm. 10, pp. 2026-2031

  2. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  3. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: A new model to understand chemoresistance

    Blood, Vol. 127, Núm. 15, pp. 1896-1906

2015

  1. Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma

    Haematologica

  2. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

  3. The cellular origin and malignant transformation of Waldenström macroglobulinemia

    Blood, Vol. 125, Núm. 15, pp. 2370-2380

  4. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma

    Haematologica, Vol. 100, Núm. 2, pp. e53-e55

  5. Treatment for patients with newly diagnosed multiple myeloma in 2015

    Blood Reviews, Vol. 29, Núm. 6, pp. 387-403